All Photos
We’re launching an editorial series on our work to advance economic sustainability in #cancer care. Read the first piece from JuHae Son, Senior Director of Access & Policy Strategy, on how pricing & payment reforms can help make cancer care more affordable
Announcing the first-ever song created in collaboration with members of the spinal muscular atrophy (SMA) community from beginning to end, called SPACES! Tune in on 11/9 at 10am PT/ 1pm ET for the premiere of the song & music video. Learn more:
This #LungCancerAwarenessMonth, we’re encouraged by the progress made for treating early-stage disease. Historically, about half of all people with early lung cancer experience cancer recurrence after surgery, but now immunotherapy may bring new hope. #LCSM
#DYK we were the first biotech company to set greenhouse gas emissions & water-use reduction goals back in 2006? We're at #COP26 in support of #ClimateAction, because we believe in a just & healthy world for all. Learn more:
ICYMI: We are proud to announce @US_FDA approved our treatment for wet age-related macular degeneration, a leading cause of blindness for people aged 60 and over. Learn more:
Retweeted by Genentech
We're among the top 10 companies named to the 2021 @ScienceCareers Top Employer List! Thanks for including us on the list for two decades in a row as a #SCTopEmployer. Learn more about the award here:
Hear from Aviv Regev, Head of Genentech Research & Early Development on how applying #AI and #machinelearning methods will help us advance the drug discovery process in the video below:
#Breaking: The @US_FDA has approved our first-of-its kind treatment for wet age-related macular degeneration. This is the first treatment in 15 years to provide an alternative to eye injections needed as often as once a month, a standard of care.…
Thank you, @HLTHEVENT and @BloombergTV for inviting our CEO Alexander Hardy to talk about tackling #COVID19, addressing inequities and improving access to care. #HLTH2021…
ICYMI: @US_FDA approved our #immunotherapy as adjuvant treatment for certain types of early non-small cell #lungcancer, bringing an urgently needed new treatment option to patients. Learn more:
Ahead of #CHEST2021, we talked with Dr. Gupta, practicing pulmonologist & Senior Medical Director at our company about idiopathic pulmonary fibrosis (IPF), our ongoing research in the space & his predictions for the future of IPF management. Learn more:
#Breaking: @US_FDA approved our #immunotherapy for certain people with early non-small cell #lungcancer, providing the first and only adjuvant immunotherapy in this setting after years of limited advances. Learn more:…
Understanding the science behind biomarkers in Alzheimer's disease has always been an important part of our research and development efforts to improve patient treatment and care. Learn more about our ongoing efforts here:
Today we announced new findings from our ongoing studies demonstrating long-term efficacy in reducing the risk of relapses in people living with neuromyelitis optica spectrum disorder (#NMOSD). Learn more:…
Congratulations to @aidocmed, winner of the New Health Application of #AI category at the 2021 @ucsfhealthhub award! Thank you to @Roche for helping us sponsor this event.
#ICYMI our CEO Alexander Hardy spoke with @technology about our role in the fight against Covid-19 and what lies ahead for the industry. Learn more:
We were recently honored at the #UCSFHealthAwards2021, which recognizes the best new innovations in life sciences. We are proud of our ongoing collaborations with @UCSF!…
We’re announcing new long-term data underscoring the importance of early treatment in multiple sclerosis (#MS), as well as findings on the impact of #COVID19 for those living with MS. Learn more:… #ECTRIMS2021
Through our partnerships with clinical trial sites like @UTHealthSAMDA, we’re working to increase diversity in clinical research, including Hispanic and Latinx patients who have long been underrepresented. Hear from @mpdrc on why this work is so important. #HispanicHeritageMonth
Check out our new account dedicated to keeping you up to date on our work in ophthalmology. Welcome to Twitter, @GenentechEye!…
Tune in to hear from our three Golden Ticket finalists as they pitch their scientific innovation and make their case for a year of free lab space. We will also share some insights into our partnering activities and what makes for a great collaboration.…
Congratulations to our Chief People and Culture Officer Cynthia Burks, who has been honored by the @SFBusinessTimes as one of the Most Influential Women In Bay Area Business, and to Chief Diversity Officer Quita Highsmith for receiving an SFBT Inspire Award this year! #SFBTwomen
#Breaking: @US_FDA has granted Breakthrough Therapy Designation to our investigational anti-amyloid beta antibody for the treatment of #AlzheimersDisease. Learn more:…
We’re sharing our latest ophthalmology research at the upcoming #ASRS2021 meeting. Follow @GenentechEye for updates on what we’ll be presenting:
We’re partnering with @WithoutViolence to prevent childhood trauma and advance health equity through targeted funding and collaborative learning #AllInForKids…
Tune in tomorrow Oct. 7th at 9:30 am PT to hear about the road ahead for health care and patient access with @BrignoniYolanda from @axios and our very own SVP of Access and External Affairs Fritz Bittenbender. Register today:…
We’re reducing our environmental impact and associated air pollution to reach our 2029 goal of cutting emissions by 75% without offsets. Join us in signing the @CleanAirDay Pledge here:
This year we're sponsors of the 2021 @ucsfhealthhub awards with @Roche in the New Health Application of #AI category. Good luck to all of the nominees!
#Breaking: We’re announcing new data that further advances the science in neuromyelitis optica spectrum disorder (#NMOSD) and multiple sclerosis (#MS) at #ECTRIMS2021. Learn more:…
Congratulations to the 8 #AllinForKids grantees leading the Bay Area’s success in interrupting childhood trauma & advancing health equity. We're proud to contribute $5M to this initiative in partnership with @WithoutViolence @BlueShieldFound @SonomaFirst5:
Today, as a proud member of the @Roche Group, we celebrate 125 years of cutting-edge science and history-making medicines for generations of patients around the world.
During #BloodCancerAwarenessMonth, hear perspective from a leader in the space on the evolving blood cancer treatment landscape:
Research in @PNASNews by Shengya Cao & team describes a new method for discovering protein interactions. The method is well-suited for difficult-to-purify membrane proteins, & has broad applications in basic research & drug-discovery efforts. Read more:
Today is #InternationalPodcastDay. And what better way to celebrate the occasion than to grab a stool and raise a glass to the new season of our award-winning #podcast, Two Scientists Walk into a Bar. 🎙
#HappeningNow: Chief Diversity Officer Quita Highsmith and Global Lead Nicole Richie discuss how we can take action to rebuild trust in the healthcare system and improve experiences for all patients. Watch their conversation at #TheAtlanticFest now.
Recently, the @AmericanCancer announced our partnership to ensure everyone can #ReturnToScreening. Read more from the American Cancer Society here:
Today at #TheAtlanticFest, our Chief Diversity Officer, Quita Highsmith, will discuss how we’re working to build patient trust in the healthcare system & partnering with healthcare providers to improve health equity. Tune in to our Twitter page at 11 am PT to watch.
Today at #ASCOQLTY21, we presented data revealing unequal access to new digital #cancercare tools for Black, Hispanic and other patients of color. Confronting digital disparities is critical to achieve personalized cancer care for all.
On 9/22, our Chief Diversity Officer Quita Highsmith will join @mpdrc and @SMonroe2020 at #TheAtlanticFest to discuss new data surrounding healthcare disparities faced by medically disenfranchised patients. Register for free:
Today at 9am PT, we’re presenting new data from a Phase II study evaluating an oral selective estrogen receptor degrader (SERD) in ER-positive/HER2-negative early #breastcancer at #ESMO21.
#Breaking: New results from the pivotal study evaluating our cancer #immunotherapy as adjuvant treatment for certain types of early #lungcancer were presented today at #ESMO21 and published in @TheLancet. Learn more:…
On World Alzheimer’s Day tomorrow, Sept. 21, we’re hosting a live panel discussion at 9:00 am PT / 12:00 pm ET moderated by Dr. Rachelle Doody. Rachelle will be joined by leading voices from the Alzheimer’s disease community. Sign up here:
#Cancer of unknown primary (CUP) is difficult to treat. Our data at #ESMO21 highlights how comprehensive genomic profiling may inform a more personalized treatment plan for people living with this type of disease.
ICYMI: Neuroscientist Tracy Yuen and immunologist Ann Herman provide insight into how they're tackling multiple sclerosis (MS) in the lab in the latest episode of our #podcast, Two Scientists Walk Into a Bar. Check out S4E02 here:
We’re committed to building a diverse, inclusive & equitable workforce at all levels: Hear from Senior Manager, Lindsey Silva about how we can all work together to help foster an environment where employees can bring their authentic selves to work. #Latinx #HispanicHeritageMonth
Next week we’re participating in #TheAtlanticFest to unveil the findings of our second annual Health Equity Study focused on the experiences of medically disenfranchised patients. Tune in to see how we're addressing the root cause of health inequity.…
We look forward to engaging with providers, patient groups & policymakers for a timely #PDUFAVII reauthorization to improve FDA operations & expedite access to medicines. Learn more:
In the latest episode of our #podcast, Two Scientists Walk Into a Bar, immunologist Ann Herman and neuroscientist Tracy Yuen discuss recent advances in multiple sclerosis (MS) research that may lead to future therapies. Listen to the full episode here:
What can be done to improve equity in Alzheimer’s disease care? We’re convening experts from across the community this #WorldAlzheimersDay to discuss this and other big questions in the AD space during a Linkedin event on September 21. Register here:
Twiends™ uses the Twitter™ API, displays it's logo & trademarks, and is not endorsed or certified by them. These items remain the property of Twitter. We do not sell followers, we only provide display advertising. Bots & fake accounts are not permitted on twiends. © 2009
Grow Your Twitter Free
Want To Grow Your Twitter?
We help other people find and follow you on Twitter.
Key Info:
Started in 2009
Over 6 million signups
Country targeting provided
We never auto tweet to your timeline
We never auto follow others
We actively moderate our community
Please Share
Please upgrade your browser  chrome